Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reverse Transcriptase Inhibitors in Aicardi-Goutières Syndrome
NCT04731103Phase 2Completed
- Sponsor
- University of Edinburgh
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abacavir, lamivudine, zidovudine in Aicardi-Goutières syndrome (AGS), sponsored by University of Edinburgh. Started Aug 2022; status: completed.
02
Drugs
abacavirlamivudinezidovudine
03
Conditions
Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on NCT04731103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731103.